Biolase Gets FDA Nod for EPIC 10S

Zacks

Recently, a pioneer in manufacturing and distributing dental lasers, BIOLASE, Inc. (BIOL) obtained regulatory clearance from the U.S. Food & Drug Administration (:FDA) for its EPIC 10S soft tissue diode laser. Last month the company received FDA approval for another diode soft tissue laser, Diolase 10 diode soft tissue laser. EPIC 10S has been approved for surgical use across more than 19 medical markets for more than 80 different indications.

The 19 medical markets include plastic surgery, oral surgery, orthopedics, dermatology, podiatry, gynecology, cardiac surgery, urology, thoracic surgery, vascular surgery, aesthetics, ophthalmology, general surgery, and ear, nose and throat among others. Additionally, this product is also cleared by the FDA for temporary pain relief and tooth whitening.

BIOLASE's diode lasers are used as an alternative to the ideal surgical devices, which are traumatic and invasive in nature. EPIC 10S, a part of Biolase’s diode lasers, consumes low power, generates less heat and increases comfort while surgery. The product operates under 940nm wavelength, under which chances of infection and contamination are reduced considerably.

The FDA clearance allows the company to expand its EPIC 10S platform along with the consumable business across a wide market of multi-billion dollar medical products..

BIOLASE develops and markets lasers and related products for applications in medicine and dentistry. Its key products, the dental laser systems, perform a broad spectrum of dental procedures, including cosmetic and complex surgical applications. To date the company has worked with over 340 patents and patent pending technologies made to deliver efficient performance with speed, less pain and more efficiency. To date, the company has sold more than 22,000 lasers.

Currently Biolase carries a Zacks Rank #3 (Hold). Other medical and laser instrument stocks worth considering are Cutera, Inc. (CUTR), Given Imaging Ltd. (GIVN) and Cepheid (CPHD), all of which carry a Zacks rank #1 (Strong Buy).

Read the Full Research Report on BIOL

Read the Full Research Report on CPHD

Read the Full Research Report on CUTR

Read the Full Research Report on GIVN

Zacks Investment Research



More From Zacks.com

Rates

View Comments (0)